Table 1. Immunization and challenge schedules used in this study.

Vaccine	Primary Immunization		Booster Immunization**		Challenge Strain	Challenge***		Time of challenge (Days)****
	Dose (CFU)	Route	Dose	Route		Dose (CFU)	Route
emrA1 Mutant	1x106	i.n.	-	-	Ft LVS	1x107	i.n.	42
	1x106	i.n.	-	-	Ft LVS	1x108	i.n.	42
	1x106	i.n.	-	-	Ft LVS	1x107	i.n.	75
	1x106	i.n.	-	-	Ft SchuS4 #	32	i.n.	21
	1x106	i.n.	1x106	i.n.	Ft SchuS4	38	i.n.	42
	1x106	i.n.	1x106	i.d.	Ft SchuS4	17	i.n.	42
	1x106	i.d.	1x106	i.n.	Ft SchuS4	17	i.n.	42
	1x103	i.n.	1x103	i.d.	Ft SchuS4	23	i.n.	42
	1x103	i.d.	1x103	i.n.	Ft SchuS4	24	i.n.	42
emrA1 Mutant-mAb complex*	1x106	i.n.	-	-	Ft SchuS4	32	i.n.	21
	1x106	i.n.	1x106	i.d.	Ft SchuS4	17	i.n.	42
	1x106	i.d.	1x106	i.n.	Ft SchuS4	17	i.n.	42

*emrA1 mutant was complexed with 5μg/ml of anti-Ft LVS LPS monoclonal antibodies

**Booster vaccinations were administered on day 21 of the primary immunization

***Equal doses of Ft LVS or SchuS4 were administered i.n. to unvaccinated control mice

****Days post-primary immunization

^# The target dose for all Ft SchuS4 challenge experiments was 25 CFU. The actual CFU administered are shown.

i.n. = Intranasal; i.d. = Intradermal; mAb = Monoclonal antibodies.